MedTrace Logo

Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer

NCT02424682 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2016-11-02

No results posted yet for this study

Summary

This study was designed to evaluate safety and tolerability of Herceptin as treatment for patients with human epidermal growth factor receptor 2 (HER-2) positive metastatic breast cancer. Frequency, characteristics and severity of adverse events (AE) and serious adverse events (SAE) were followed to evaluate the safety of Herceptin in patients with HER2 positive metastatic breast cancer.

Conditions

  • Breast Cancer, Metastatic Breast Cancer

Interventions

OTHER

No intervention

No intervention administered in this study

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Serbia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02424682 on ClinicalTrials.gov